Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients with Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 57
- Registration Number
- NCT06732856
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 56
- Registration Number
- NCT06657690
- Locations
- 🇨🇳
Fifth affiliated hosptial of Sun-yat Sen university, Zhuhai, Guangzhou, China
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06598917
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 40
- Registration Number
- NCT06555471
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 42
- Registration Number
- NCT06487715
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 53
- Registration Number
- NCT06451211
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC
- Conditions
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT06427005
- Locations
- 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 32
- Registration Number
- NCT06385873
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.